Gianluca Piatelli

Gianluca Piatelli

Auto-generated profile, based on publicly available information

Gianluca Piatelli

Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2012 in Journal of Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
PMPatrizia De Marco
Patrizia De Marco
EMElisa Merello
Elisa Merello
ACAlessandro Consales
Alessandro Consales
GPGianluca Piatelli
Gianluca Piatelli
ACArmando Cama
Armando Cama
VCValeria Capra
Valeria Capra
Neural tube defects are severe malformations affecting 1/1,000 live births. The planar cell polarity pathway controls the neural tube closure and has been implicated in the pathogenesis of neural tube defects both in animal models and human cohorts. In mouse disruption ofDvl2alone (Dvl2−/−) orDvl2andDvl3(Dvl2−/−;Dvl3+/−,Dvl2+/−;Dvl3−/−) results in incomplete neurulation, suggesting a role for Disheveled in neural tube closure. Disheveled is a multifunctional protein that is involved in both the canonical Wnt signaling and the noncanonical planar cell polarity pathway. In this study, we analyzed the role of the human orthologsDVL2andDVL3in a cohort of 473 patients with neural tube defects. Rare variants were genotyped in 639 ethnically matched controls. We identified seven rare missense mutations that were absent in all controls analyzed. Two of these mutations, p.Tyr667Cys and p.Ala53Val, identified inDVL2were predicted to be detrimental in silico. Significantly, a 1-bp insertion (c.1801_1802insG) in exon 15 ofDVL2predicted to lead to the truncation of the protein was identified in a patient with a complex form of caudal agenesis. In summary, we demonstrate a possible role for rare variants inDVL2gene as risk factors for neural tube defects.

18 February 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AAAndrea Accogli
Andrea Accogli
MPMattia Pacetti
Mattia Pacetti
PFPietro Fiaschi
Pietro Fiaschi
MPMarco Pavanello
Marco Pavanello
GPGianluca Piatelli
Gianluca Piatelli
VCValeria Capra
Valeria Capra

19 June 2013 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
FSFrancesca Secci
Francesca Secci
ACAlessandro Consales
Alessandro Consales
PMPaolo Merciadri
Paolo Merciadri
GRGiuseppe Marcello Ravegnani
Giuseppe Marcello Ravegnani
GPGianluca Piatelli
Gianluca Piatelli
ACArmando Cama
Armando Cama

16 February 2016 in World Neurosurgery
Verified
Journal Article
Closed access
PDF file
PFPietro Fiaschi
Pietro Fiaschi
MSMariasavina Severino
Mariasavina Severino
GRGiuseppe Marcello Ravegnani
Giuseppe Marcello Ravegnani
GPGianluca Piatelli
Gianluca Piatelli
ACAlessandro Consales
Alessandro Consales
MPMarco Pavanello
Marco Pavanello

2 January 2025 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
GGGabriele Gaggero
Gabriele Gaggero
TBTeresa Battaglia
Teresa Battaglia
VAVirginia Andreotti
Virginia Andreotti
ARAndrea Rossi
Andrea Rossi
MIMarta Ingaliso
Marta Ingaliso
Valerio Gaetano VelloneValerio Gaetano Vellone
Valerio Gaetano Vellone
Introduction: Giant cell tumor of bone (GCTB) is a rare, typically benign neoplasm that primarily affects long bones in adults, with clival involvement being extremely rare, particularly in pediatric cases: a mini-review shows a total of 28 described cases, of which only 5 were truly pediatric (within 14 years of age). Surgery is the treatment of choice, and Denosumab is reported to be the most effective drug therapy. To date, the GCTB’s molecular hallmark is the somatic mutation p.Gly34Trp, at the H3F3A gene (H3.3 p.Gly34Trp mutation), but in this case, the mutation H3.3 p.Gly35Trp was identified. Case Presentation: A 9-year-old female presented with progressive ocular pain, ptosis, and diplopia. MRI revealed a 42 × 32 × 30 mm mass in the clivus and sphenoid body. The patient underwent partial resection, and histology confirmed GCTB. Molecular testing revealed the presence of the H3.3 p.Gly35Trp mutation, and we demonstrate that this is the true mutation associated with GCTB, not the previously described (H3.3 p.Gly34Trp). Due to residual tumor tissue, the patient was treated with Denosumab, a RANKL inhibitor. During a 2-year follow-up, the tumor size stabilized, and no significant adverse effects were observed. Conclusion: This case represents the first pediatric clival GCTB harboring the H3.3 p.Gly35Trp mutation. Molecular diagnostics played a crucial role in confirming the diagnosis and demonstrating that the true mutation harbored by GCTB is H3.3 p.Gly35Trp and not the formerly described (H3.3 p.Gly34Trp). Denosumab therapy effectively controlled the tumor without major side effects, although long-term treatment duration and safety require further study. Cite this article as: Gaggero G, Battaglia T, Andreotti V, et al. A rare pediatric giant cell tumor of the clivus bone, H3.3 p.Gly35Trp-mutated: case report and mini-review of the literature. Turk Arch Pediatr. 2025;60(1):84-91.

16 September 2025 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
GGGabriele Gaggero
Gabriele Gaggero
CAChiara Trambaiolo Antonelli
Chiara Trambaiolo Antonelli
GPGianluca Piatelli
Gianluca Piatelli
CMClaudia Milanaccio
Claudia Milanaccio
Not required for Clinical Vignette. Keywords: cellular cannibalism medulloblastoma pediatric